Oruka Therapeutics Inc (ORKA)

$38.91 +0.09 (0.23%)
Market Cap 1.93B
Revenue (ttm) 0.00
Net Income (ttm) -105.43M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,257,400
Avg Vol 487,350
Day's Range N/A - N/A
Shares Out 49.54M
Stochastic %K 66%
Beta -0.38
Analysts Strong Sell
Price Target $61.23

Company Profile

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 1 trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORK...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 606 7910
Website: orukatx.com
Address:
855 Oak Grove Avenue, Suite 100, Menlo Park, United States
thesheiktrader
thesheiktrader Mar. 18 at 6:17 PM
$ORKA 50 Dominga maybe this week
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 18 at 6:10 PM
$ORKA RSI: 69.15, MACD: 1.9114 Vol: 3.31, MA20: 35.22, MA50: 33.58 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
blessme1
blessme1 Mar. 17 at 2:38 PM
$ORKA 50s incoming
0 · Reply
erevnon
erevnon Mar. 16 at 7:59 PM
Leerink Partners maintains Oruka Therapeutics $ORKA at Outperform and raises the price target from $58 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
thesheiktrader
thesheiktrader Mar. 16 at 2:31 PM
$ORKA Leto see in 50 in few months
1 · Reply
topstockalerts
topstockalerts Mar. 15 at 2:43 PM
Top Gainers PT2 $PLYX $VACHU $STAK $ISPC $ORKA
1 · Reply
DanFitz
DanFitz Mar. 13 at 11:54 PM
Here's how we traded Oruka Therapeutics $ORKA. And it's still going... https://youtu.be/ImEDhfFlqbQ
0 · Reply
topstockalerts
topstockalerts Mar. 13 at 10:54 PM
Top Gainers PT2 $PLYX $VACHU $STAK $ISPC $ORKA
0 · Reply
topstockalerts
topstockalerts Mar. 13 at 8:42 PM
Top Gainers PT2 $PLYX $VACHU $STAK $ISPC $ORKA
0 · Reply
NeverFadeTheOracle
NeverFadeTheOracle Mar. 13 at 7:04 PM
$ORKA Feels good
0 · Reply
Latest News on ORKA
Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Mar 12, 2026, 4:05 PM EDT - 9 days ago

Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Oruka Therapeutics: A Potential Future Psoriasis Play

Feb 25, 2026, 10:03 AM EST - 24 days ago

Oruka Therapeutics: A Potential Future Psoriasis Play

Oruka Therapeutics to Participate in Multiple Upcoming Conferences

Feb 9, 2026, 7:00 AM EST - 5 weeks ago

Oruka Therapeutics to Participate in Multiple Upcoming Conferences

Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001

Jan 12, 2026, 7:00 AM EST - 2 months ago

Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001

Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 7:00 AM EST - 2 months ago

Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Oruka Therapeutics: ORKA-001 For Psoriasis In Focus As 2026 Phase 2 Data Nears

Jan 5, 2026, 9:51 PM EST - 2 months ago

Oruka Therapeutics: ORKA-001 For Psoriasis In Focus As 2026 Phase 2 Data Nears

Oruka Therapeutics Announces New Board Member and Board Transition

Dec 11, 2025, 4:01 PM EST - 3 months ago

Oruka Therapeutics Announces New Board Member and Board Transition

Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 12, 2025, 4:05 PM EST - 4 months ago

Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oruka Therapeutics to Present at Multiple November Investor Conferences

Oct 29, 2025, 7:00 AM EDT - 5 months ago

Oruka Therapeutics to Present at Multiple November Investor Conferences

Oruka Therapeutics Announces $180 Million Private Placement

Sep 17, 2025, 1:02 AM EDT - 6 months ago

Oruka Therapeutics Announces $180 Million Private Placement

Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001

Sep 17, 2025, 1:00 AM EDT - 6 months ago

Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001

Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 11, 2025, 4:04 PM EDT - 7 months ago

Oruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September

Jul 21, 2025, 7:00 AM EDT - 8 months ago

Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September

Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer

Jul 1, 2025, 4:01 PM EDT - 9 months ago

Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer

Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference

May 21, 2025, 7:00 AM EDT - 10 months ago

Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody

May 20, 2025, 4:01 PM EDT - 10 months ago

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody

Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025, 4:15 PM EDT - 11 months ago

Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Oruka Therapeutics to Present at Bank of America Securities 2025 Health Care Conference

Apr 29, 2025, 7:00 AM EDT - 11 months ago

Oruka Therapeutics to Present at Bank of America Securities 2025 Health Care Conference

Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting

Mar 7, 2025, 8:30 AM EST - 1 year ago

Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting

Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 6, 2025, 4:09 PM EST - 1 year ago

Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Oruka Therapeutics to Present at Multiple March Investor Conferences

Feb 19, 2025, 7:00 AM EST - 1 year ago

Oruka Therapeutics to Present at Multiple March Investor Conferences

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody

Dec 19, 2024, 7:00 AM EST - 1 year ago

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody

Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)

Dec 18, 2024, 7:00 AM EST - 1 year ago

Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)

Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 13, 2024, 4:25 PM EST - 1 year ago

Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress

Sep 25, 2024, 7:08 AM EDT - 1 year ago

Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress

Oruka Therapeutics Announces $200 Million Private Placement

Sep 12, 2024, 7:05 AM EDT - 1 year ago

Oruka Therapeutics Announces $200 Million Private Placement

ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock Split

Aug 29, 2024, 4:50 PM EDT - 1 year ago

ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock Split

ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics

Aug 26, 2024, 7:30 PM EDT - 1 year ago

ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics

ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics

Aug 23, 2024, 4:30 PM EDT - 1 year ago

ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics

ARCA biopharma Declares Special Dividend in Connection with the Proposed Merger with Oruka Therapeutics

Aug 16, 2024, 4:15 PM EDT - 1 year ago

ARCA biopharma Declares Special Dividend in Connection with the Proposed Merger with Oruka Therapeutics

ARCA biopharma Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 1, 2024, 4:15 PM EDT - 1 year ago

ARCA biopharma Announces Second Quarter 2024 Financial Results and Provides Corporate Update

ARCA BIOPHARMA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ARCA biopharma, Inc. - ABIO

May 10, 2024, 6:34 PM EDT - 2 years ago

ARCA BIOPHARMA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ARCA biopharma, Inc. - ABIO

ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update

Apr 25, 2024, 4:15 PM EDT - 2 years ago

ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update

ARCA BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ARCA biopharma, Inc. - ABIO

Apr 5, 2024, 1:27 PM EDT - 2 years ago

ARCA BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ARCA biopharma, Inc. - ABIO

Arca Biopharma stock ($ABIO) soars on merger news

Apr 3, 2024, 11:38 AM EDT - 2 years ago

Arca Biopharma stock ($ABIO) soars on merger news

ARCA biopharma and Oruka Therapeutics Announce Merger Agreement

Apr 3, 2024, 7:30 AM EDT - 2 years ago

ARCA biopharma and Oruka Therapeutics Announce Merger Agreement

ARCA biopharma Announces 2023 Financial Results

Feb 1, 2024, 4:35 PM EST - 2 years ago

ARCA biopharma Announces 2023 Financial Results

ARCA biopharma Announces Third Quarter 2023 Financial Results

Oct 18, 2023, 4:25 PM EDT - 2 years ago

ARCA biopharma Announces Third Quarter 2023 Financial Results

ARCA biopharma Announces Second Quarter 2023 Financial Results

Jul 21, 2023, 4:25 PM EDT - 2 years ago

ARCA biopharma Announces Second Quarter 2023 Financial Results

ARCA biopharma Announces First Quarter 2023 Financial Results

Apr 24, 2023, 4:25 PM EDT - 3 years ago

ARCA biopharma Announces First Quarter 2023 Financial Results

ARCA biopharma Announces 2022 Financial Results and Provides Corporate Update

Feb 24, 2023, 4:20 PM EST - 3 years ago

ARCA biopharma Announces 2022 Financial Results and Provides Corporate Update

James Flynn Joins ARCA biopharma Board of Directors

Dec 19, 2022, 4:05 PM EST - 3 years ago

James Flynn Joins ARCA biopharma Board of Directors

ARCA biopharma Announces Third Quarter 2022 Financial Results

Oct 28, 2022, 4:15 PM EDT - 3 years ago

ARCA biopharma Announces Third Quarter 2022 Financial Results

ARCA biopharma Announces Second Quarter 2022 Financial Results

Aug 2, 2022, 4:15 PM EDT - 3 years ago

ARCA biopharma Announces Second Quarter 2022 Financial Results

Jacob Ma-Weaver Joins ARCA biopharma Board of Directors

Jun 21, 2022, 4:05 PM EDT - 4 years ago

Jacob Ma-Weaver Joins ARCA biopharma Board of Directors

ARCA biopharma Retains Ladenburg Thalmann to Support Strategic Options Review

May 5, 2022, 4:15 PM EDT - 4 years ago

ARCA biopharma Retains Ladenburg Thalmann to Support Strategic Options Review

ARCA biopharma: Activist's Pressure Could Make This Into A Liquidation Play

May 3, 2022, 11:50 AM EDT - 4 years ago

ARCA biopharma: Activist's Pressure Could Make This Into A Liquidation Play

thesheiktrader
thesheiktrader Mar. 18 at 6:17 PM
$ORKA 50 Dominga maybe this week
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 18 at 6:10 PM
$ORKA RSI: 69.15, MACD: 1.9114 Vol: 3.31, MA20: 35.22, MA50: 33.58 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
blessme1
blessme1 Mar. 17 at 2:38 PM
$ORKA 50s incoming
0 · Reply
erevnon
erevnon Mar. 16 at 7:59 PM
Leerink Partners maintains Oruka Therapeutics $ORKA at Outperform and raises the price target from $58 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
thesheiktrader
thesheiktrader Mar. 16 at 2:31 PM
$ORKA Leto see in 50 in few months
1 · Reply
topstockalerts
topstockalerts Mar. 15 at 2:43 PM
Top Gainers PT2 $PLYX $VACHU $STAK $ISPC $ORKA
1 · Reply
DanFitz
DanFitz Mar. 13 at 11:54 PM
Here's how we traded Oruka Therapeutics $ORKA. And it's still going... https://youtu.be/ImEDhfFlqbQ
0 · Reply
topstockalerts
topstockalerts Mar. 13 at 10:54 PM
Top Gainers PT2 $PLYX $VACHU $STAK $ISPC $ORKA
0 · Reply
topstockalerts
topstockalerts Mar. 13 at 8:42 PM
Top Gainers PT2 $PLYX $VACHU $STAK $ISPC $ORKA
0 · Reply
NeverFadeTheOracle
NeverFadeTheOracle Mar. 13 at 7:04 PM
$ORKA Feels good
0 · Reply
Ava_Sanders_47
Ava_Sanders_47 Mar. 13 at 6:40 PM
$ORKA
0 · Reply
thesheiktrader
thesheiktrader Mar. 13 at 6:00 PM
$ORKA always right… this stock will be touching 70 end of the year
0 · Reply
Pika_Capital
Pika_Capital Mar. 13 at 5:22 PM
$ORKA ‼️‼️
0 · Reply
topstockalerts
topstockalerts Mar. 13 at 4:46 PM
$ORKA Very thin microcap where price can move quickly with limited volume. If a new filing or announcement hits, scanners usually bring traders in fast.
0 · Reply
erevnon
erevnon Mar. 13 at 4:12 PM
Stifel maintains Oruka Therapeutics $ORKA at Buy and raises the price target from $47 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
blessme1
blessme1 Mar. 13 at 3:21 PM
$ORKA patiently waiting for those Haltom ups
1 · Reply
thesheiktrader
thesheiktrader Mar. 13 at 2:43 PM
$BIAF & $ORKA winner Winner chicken dinner
0 · Reply
thesheiktrader
thesheiktrader Mar. 13 at 2:40 PM
$ORKA BOOM the bull has just started
0 · Reply
WAJeff
WAJeff Mar. 13 at 2:26 PM
$ORKA Had this sell at 36.50 but it just hit a 39.51 52 week high
0 · Reply